3 years ago

CORRIGENDUM

Fioretto P, Del Prato S, Buse JB, Goldenberg R, Giorgino F, Reyner D, Langkilde AM, Sjöström CD, Sartipy P, On Behalf of the DERIVE Study Investigators. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes, Obesity and Metabolism 2018; 20(11): 2532–2540. https://doi.org/10.1111/dom.13413

In the article ‘Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study’, the ‘total’ values in Table 3 are incorrect, due to an overcounting error in the number of patients experiencing hypoglycaemic events. As some patients may have had both ‘minor’ and ‘other’ events, a summation of both categories to give the ‘total’ value was incorrect. The corrected values are shown below:

Table 3. Summary of hypoglycaemia events (safety analysis set)

-Abstract Truncated-

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.

Dapagliflozin 10 mg (N = 160) Placebo (N = 161)
Patients, n (%) Events, n Patients, n (%) Events, n
Total 17 (10.6) 44 18 (11.2) 62
Major 0 0 0 0
Minor 12 (7.5) 34 16 (9.9) 53
Other